Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Phase 1 Terminated 227 enrolled Mythic Therapeutics

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).

Timeline

Start: 2023-03-23
Primary completion: 2025-10-31
Completion: 2025-11-07

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Publications

Gera N, Fitzgerald KM, Ramesh V, Patel P, Kanojia D, Colombo F, Kien L, Aoyama S, Xu L, Jean J, Deshpande AM, Comb WC, Chittenden T, Fiske BP. MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells. Mol Cancer Ther. 2024 Sep 4;23(9):1282-1293. doi: 10.1158/1535-7163.MCT-23-0784.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MYTX-011	Other / unclassified	—	Intravenous